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Tumour progression depends on several sequential events that 
include the microenvironment remodelling processes and the switch 
to the angiogenic phenotype, leading to new blood vessels 
recruitment. Non-invasive imaging techniques allow the monitoring 
of functional alterations in tumour vascularity and cellularity. The 
aim of this work was to detect functional changes in vascularisation 
and cellularity through Dynamic Contrast Enhanced (DCE) and 
Diffusion Weighted (DW) Magnetic Resonance Imaging (MRI) 
modalities during breast cancer initiation and progression of a 
transgenic mouse model (BALB-neuT mice). Histological examination 
showed that BALB-neuT mammary glands undergo a slow neoplastic 
progression from simple hyperplasia to invasive carcinoma, still 
preserving normal parts of mammary glands. DCE-MRI results 
highlighted marked functional changes in terms of vessel 
permeability (Ktrans, volume transfer constant) and vascularisation 
(vp, vascular volume fraction) in BALB-neuT hyperplastic mammary 
glands if compared to BALB/c ones. When breast tissue progressed 
from simple to atypical hyperplasia, a strong increase in DCE-MRI 
biomarkers was observed in BALB-neuT in comparison to BALB/c 
mice (Ktrans = 5.3 ± 0.7E-4 and 3.1 ± 0.5E-4; vp = 7.4 ± 0.8E-2 and 
4.7 ± 0.6E-2 for BALB-neuT and BALB/c, respectively) that remained 
constant during the successive steps of the neoplastic 
transformation. Consistent with DCE-MRI observations, microvessel 
counting revealed a significant increase in tumour vessels. Our study 
showed that DCE-MRI estimates can accurately detect the angiogenic 
switch at early step of breast cancer carcinogenesis. These results 
support the view that this imaging approach is an excellent tool to 
characterize microvasculature changes, despite only small portions 







Breast cancer typically evolves through a multistep progression 
process, starting from epithelial hyperplasia and progressing to 
carcinoma in situ (CIS) and finally to metastatic carcinomas.[1] 
Tumour microenvironment is often claimed as a key player in tumour 
biological transformations into consequent more aggressive steps. 
To ensure tumour growth and proliferation from early stages of 
progression, tumour cells induce the formation of new blood vessels 
through a vascular remodelling process termed “angiogenic switch.” 
This event represents the turn-on step that allows cancer cells to 
invade and growth out their primary niche and it is becoming a key 
target for novel anti-cancer therapies.[2, 3] In particular, tumour 
associated neo-blood vessels display structural and functional 
abnormalities, mainly due to the imbalanced regulation between 
pro- and anti-angiogenic factors that make them tortuous and leaky. 
This chaotic and unstructured vasculature is responsible of irregular 
perfusion that determines areas characterized by different pO2.[4, 5] 
Since tumour microvessels exhibit such unique properties, the real 
time monitoring of alterations in vascularity using non-invasive 
imaging techniques appears to be the most suitable approach to 
succeed in early breast cancer detection and characterization. 
Imaging may report on tumour heterogeneity and identify more 
aggressive regions to directly guide biopsies and radiotherapy. 
Among the imaging techniques, Magnetic Resonance Imaging (MRI) 
is the only modality that combines high spatial resolution and 
excellent tissue contrast with functional information.[6, 7] The 
dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) 
technique involves the injection of a paramagnetic contrast agent 
(CA) and evaluates the differential enhancement produced upon 
time by its extravasation through leaky tumour vessels.[7, 8] Maps of 
tumour tissue parameters such as vascular permeability and 
perfusion (Ktrans), extracellular volume fraction (ve), and blood plasma 
volume fraction (vp) can be obtained by using pharmacokinetic 
compartment models.[9] Besides DCE-MRI, the diffusion weighted 
imaging technique (DWI) provides additional information on tumour 
microenvironment. The apparent diffusion coefficient (ADC) is 
inversely dependent on water movements across the cell membrane 
and reflects tissue changes at cellular level. Increases in ADC 
correspond to decreases in cellular size or number of cells, due to 
apoptosis or necrosis, whereas lower ADC values correspond to a 
state of tumour progression, increased fibrosis or interstitial 
oedema.[10] Much attention is currently devoted to the combined 
use of DCE- and DW-MRI; most of the reported studies have shown 
the ability of MRI functional parameters to assess early response to 
neoadjuvant chemotherapy and antiangiogenic treatments at clinical 
and preclinical settings.[11-17] 
Moreover, there is an increase interest in using DCE- and DW-MRI in 
breast cancer characterization and subtyping. Malignant and benign 
breast tumours have been clearly differentiated by DWI, with lower 
ADC values recorded in malignant tumours compared to benign 
lesions.[18, 19] In addition, pharmacokinetic parameters obtained by 
DCE-MRI represent potential candidates for luminal and basal breast 
cancer identification.[20] For longitudinal studies of breast 
carcinogenesis, the use of transgenic mouse models might provide 
evident advantages at preclinical settings, compared to xenograft 
ones. Xenograft models are only representative of advanced stages 
of cancer, whereas transgenic mice recapitulate the stepwise 
progression and typical features of several human cancers, 
preserving the interaction between tumours and the surrounding 
microenvironment.[21] In the current study, we used the BALB-neuT 
transgenic murine model that shows a human-like breast cancer 
development, including mammary hyperplasia, atypical hyperplasia, 
CIS and invasive breast cancer.[22] The BALB-neuT mice overexpress 
the activated form of the rat ErbB2 (Her/2-neu) oncogene, whose 
amplification is observed in 20–30% of human breast cancer. The aim 
of the present study was to evaluate whether DCE- and DW-MRI 
modalities could detect functional tumour microenvironment 
changes along the multistep carcinogenesis process observed in the 
BALB-neuT model, before palpable mass formation, compared to 
normal mammary glands of BALB/c mice. Immunohistochemistry 
(IHC) analysis of the tumor microvasculature and cellularity was also 




Material and Methods 
Mice 
BALB/c mice were purchased from Charles River Laboratories (Calco, 
Italy), whereas BALB-neuT mice[22] were bred at the Department of 
Molecular Biotechnology and Health Science, University of Torino, 
Italy. Mice were maintained in specific pathogen-free conditions 
(Allentown Caging Equipment, Allentown) and treated in accordance 
with the University Ethical Committee and European guidelines 
under directive 2010/63. In BALB-neuT transgenic mice model 
mammary gland cells transform progressively into well distinctly 
morphological stages, namely simple hyperplasia, atypical 
hyperplasia, CIS and invasive carcinoma.[23, 24] 
DCE-MR and DW-MR imaging experiments 
MRI experiments were performed by imaging the left and right 
fourth mammary glands of female mice. Mammary glands at 
different histological stages of breast cancer progression (between 5 
and 28 weeks of age) from BALB-neuT mice (n = 156) and glands 
from age-matched control littermates (n = 74) were observed. Before 
MRI analysis, mice were anesthetized by injecting a mixture of 
tiletamine/zolazepam (Zoletil 100; Virbac, Milan, Italy) 20 mg/kg and 
xylazine (Rompun; Bayer, Milan, Italy) 5 mg/kg and a 27-gauge 
catheter was introduced into the tail vein for CA injection. Mice were 
then placed supine in a solenoid Tx/Rx coil with an inner diameter of 
3.5 cm. The breath rate was monitored throughout in vivo MRI 
experiments using a respiratory probe (SAII Instruments, Stony 
Brook, NY). A phantom filled with diluted ProHance® (Bracco Imaging 
SpA, Milan, Italy) was included in the field of view (FOV), close to 
each animal, to allow correction for changes in the instrument 
performance. 
MR images were acquired on the 1 Tesla Aspect M2 MRI scanner 
(Aspect Magnet Technologies, Israel). After the scout image 
acquisition, a T2-weighted (T2w) anatomical image was acquired with 
a Fast Spin Echo sequence (TR = 2500 sec; TE = 44 msec; number of 
slices = 10; slice thickness = 1.5 mm; FOV = 40 mm; matrix = 152 × 
160; four averages; acquisition time = 3 m 20 sec). The DCE-MRI 
dynamic protocol consisted of the application of an axial T1-weighted 
(T1w) 3D spoiled Gradient Echo sequence with three initial pre-
contrast images acquisition that were followed by the injection 
through the catheter of 0.05 mmolGd/kg gadolinium binding serum 
albumin CA (Gd-AAZTA Madec, Cage Chemicals, Novara, Italy).[25] 
After injection, 47 dynamic post-contrast images were acquired with 
the following parameters: TR = 40; TE = 2.1 ms, flip angle = 60°, 
number of slices = 10, slice thickness = 1.5 mm, FOV = 40 mm, 
matrix = 128 × 128, acquisition time = 58 sec. DW-MRI was 
performed using a Spin-Echo sequence with seven different b-values 
(0, 50, 100, 150, 200, 400, 600) with the following parameters: 
TR = 500 ms; TE = 15.4 ms; number of slices = 10; slice thickness = 1.5 
mm; FOV = 40 mm; matrix = 128 × 128; 1 = average; acquisition 
time = 7 m 28 sec. 
Image analyses 
All the DCE-MRI images were analysed using an in-house developed 
software in C++ code implementing MITK 
(http://www.mitk.org/MITK), ITK and VTK libraries for the 
quantification of pharmacokinetic parameters and in MatLab 
(MathWorks, Natick, MA). 
A rigid-ITK co-registration was applied for motion correction on VFA 
and DCE image by taking the anatomical T2w image as reference. Pre-
contrast T1 has been determined using a variable flip angle fast 
gradient echo technique.[26] Dynamic post-contrast T1 relaxation 
was calculated from the signal intensity (SI) curves after conversion 
into longitudinal relaxation rate R1 (1/T1) assuming a linear 




where 1/T10 is the pre contrast longitudinal relaxation rate, 1/T1 is 
the post contrast longitudinal relaxation rate and r1p is the 
longitudinal relaxivity of the CA that was assumed to be equal to the 
value (40 mM−1/sec) measured in blood serum. The extended Tofts' 
model with an individually measured arterial input function (AIF) has 
been used.[9] This model assumes a bidirectional exchange between 
two compartments, that is, the intravascular and the extravascular 
extracellular space (EES). To extract the kinetic parameters (Ktrans, vp, 
and kep) on a voxel-by-voxel basis, the concentration curve in the 




where Ct(t) is the CA concentration in the tissue at time t, vp is the 
fractional blood plasma volume, Cp(t) is the CA blood plasma 
concentration at time t (AIF), Ktrans is the volume transfer constant 
between the intravascular and the EES (Ktrans = kep Ve), kep is the rate 
constant from EES to blood plasma and ⊗ is the convolution 
operator. The AIF and the injection time were automatically 
determined as previously described by the software using a three-
dimensional region growing algorithm with an artery seed point 
automatically determined from the maximum increase of signal in 
the dynamic series. The accuracy of the automatic AIF identification 
was evaluated as previously described.[16] A region of interest (ROI) 
was manually drawn for both left and right IV mammary glands 
encompassing all the mammary gland tissue as visible in both T2w 
and T1w images as shown in Supporting Information Figure S1. Ktrans 
and vp mean values were extracted by an in house developed 
MATLAB script (The MathWorks, Natick, MA). 
Apparent diffusion constant (ADC) maps were calculated fitting DW-
MRI signal intensity as a function of b-values in MATLAB, working on 
a pixel by pixel basis. ADC mean values were calculated 
superimposing ADC maps on the selected ROIs. 
Histological analysis and microvessels counting 
After MRI images acquisition, BALB-neuT and BALB/c mice were 
euthanized and their skin was fixed in 4% formalin in phosphate 
saline buffer (PBS, Sigma Aldrich, Milano, Italy) at 4°C; 1 hr later 
mammary glands were gently scraped from the skin, fixed overnight 
in 4% buffered formalin solution and then embedded in paraffin. 
Tissue sections (5 μm thick) were cut from paraffin embedded blocks 
and prepared for immunohistochemistry staining. Briefly, sections 
were deparaffinized in xylol, rehydrated in graded alcohol series 
(Sigma Aldrich, Milano, Italy), then washed in PBS-Tween 0.1% (PBS-
T) and heated in a microwave oven in citrate buffer 10 mM, pH 6 
(Bioptica, Milano, Italy) for 10 min for antigen retrieval step. 
Afterwards, endogenous peroxidase activity was inhibited using 6% 
H2O2 in bidistilled water for 8 min and incubated with 10% normal 
goat serum (Sigma-Aldrich, Milano, Italy) for 1 hr at room 
temperature (RT). Slices were then incubated overnight at 4°C with 
primary rabbit polyclonal antibody against von Willebrand factor 
(vWF, 1:100, Abcam, Cambridge, UK), then with secondary goat anti-
rabbit HRP antibody (1:200, Abcam, Cambridge, UK) for 1 hr and 30 
min at RT. The immune reaction was visualized with 3,3′-
diaminobenzidine tetrahydrochloride hydrate (Sigma Aldrich, Milano, 
Italy). After washing in bidistilled water, counterstaining was 
performed with hematoxylin. For the immune-staining analysis, 
optical fields of the whole mammary glands were acquired with a 
20× magnification by using a Leica 3000 microscope. Microvessel 
density (MVD) was assessed by counting the total vessel number and 
then calculating the average of vessels per area. Positively stained 
vessels were expressed per area examined (counts/mm2) by using a 
commercially available software (Leica Application Suite, Milano, 
Italy). 
Histopathological analysis 
Formalin-fixed and paraffin-embedded sections (5 μm) of mammary 
glands were stained with hematoxylin-eosin (H&E) technique. 
Progressive morphological changes to invasive cancer were assessed 
by a pathologist blinded to the age of the animals and MR imaging 
findings. The diagnosis of simple hyperplasia, atypical hyperplasia, 
CIS and invasive carcinoma were performed according to previous 
publications.[27, 28] Glands were semi-quantitatively evaluated by 
microscopy and the presence of different histological states was 
expressed as percentage of the total mammary gland area affected. 
Cell density was determined by counting the number of nuclei cells 
on histologic specimen and divided for the FOV that consistently 
measured 713 × 532 µm by using ImageJ. 
Statistical analysis 
Statistical analysis of imaging data and microvessels counting was 
performed using GraphPad Prism 5 software (GraphPadInc, San 
Diego, California). All data are shown as mean ± SEM. One-
wayANOVA analysis and Dunn's multiple comparison test was used 
to compare (i) Ktrans and vp mean values of mammary glands in BALB-
neuT mice versus wild-type BALB/c mice at the same week of age 
and (ii) Ktrans and vp mean values in different histological findings 
within the same murine model. For all tests, a p values < 0.05 was 
considered statistically significant. 
One-way ANOVA analysis and Tukey's honestly significance 
difference test were performed to examine whether MVD and 
cellular density was significantly different in hyperplasia, atypical 
hyperplasia, CIS and invasive carcinoma of BALB-neuT mice. 
 
Results 
Vascular functional changes were observed by DCE-MRI 
when BALB-neuT mammary glands progressed from 
simple hyperplasia to atypical hyperplasia 
Figure 1a summarizes the distribution of the four histological stages 
(simple hyperplasia, atypical hyperplasia, CIS, invasive cancer) in 
mammary glands from BALB-neuT mice at different weeks of age. 
The neoplastic transformation process proceeded slowly, with the 
typical overlapping of the histological phenotypes along ageing. At 
weeks 5–7, >60% of mammary glands tissue still showed normal 
histological features, whereas 30% of the area was occupied by 
simple hyperplasia. From 8th to 13th weeks of age, atypical 
hyperplasia was present in 41% of mammary glands section and 
highly persisted at week 14–21 (45%). Histological features of CIS 
were firstly detected from week 14 (9%) and progressively increased 
to 15% at weeks 22–28. Invasive breast cancer appeared from week 
22 and occupied the 30% of the mammary glands examined. Figure 
1b shows representative H&E images of whole mammary glands for 
each morphological stage at different age of BALB-neuT mice. 
Table 1 and Figures 2a and 2b show DCE-MRI derived estimates for 
Ktrans and vp obtained for each step of BALB-neuT breast tumour 
progression and age-matched mammary glands of control BALB/c 
mice. In BALB-neuT mice, Ktrans and vp values markedly increased 
when breast tissue progressed from simple to atypical hyperplasia, 
with statistical significance for vp (p < 0.05). Further stages of tumour 
progression showed Ktrans values comparable to values obtained in 
atypical hyperplasia, whereas vp significantly increased in invasive 
breast when compared to simple hyperplasia lesions (p < 0.05). 
Signal intensity enhancement curves displayed a slow accumulation 
of the blood-pool agent, with a slight lower enhancement for the 
mammary glands at the simple hyperplasia stage (Supporting 
Information Fig. S2). Semi-quantitative estimates were calculated 
from the dynamic signal enhancement curves. Only AUC30 and 
AUC50 showed slightly lower values for simple hyperplasia in 
comparison to the other stages, despite not statistically significant 
(Supporting Information Fig. S3). BALB/c mice showed a slight 
decrease in Ktrans values along ageing of the mice that became 
significant between weeks 5–7 and weeks 22–28 (p < 0.001). 
Comparing Ktrans and vp estimates between BALB-neuT and BALB/c 
mice, similar values of both parameters were obtained in 
hyperplastic and normal mammary glands, respectively. At the time 
of atypical hyperplasia transition in BALB-neuT mice, markedly 
increased values of Ktrans and vp were observed in comparison with 
BALB/c ones. This trend is preserved along the further stages of 
BALB-neuT tumour progression. When BALB-neuT mice showed 
invasive carcinoma, significant differences for both parameters were 
observed as compared to age-related BALB/c mice (p < 0.05 for both 
Ktrans and vp). Representative parametric maps of Ktrans and vp 
superimposed on T2-weighted anatomical images for hyperplasia to 
atypical hyperplasia transition are shown in Figures 3a and 3b, 
respectively. Ve values were similar among simple hyperplasia, 
atypical hyperplasia and CIS of BALB-neuT histological stages 
(Supporting Information Fig. S4 and Table S1). An increase of Ve 
estimate was observed when mammary glands progressed to 
invasive carcinoma, however without statistical significance. DW-
MRI revealed age-related cellularity changes in BALB/c 
mammary glands 
Figure 4a shows the mean apparent diffusion coefficient (ADC) 
values along BALB-neuT tumour progression stages and age-matched 
BALB/c mice. A slightly decrease in ADC values was progressively 
observed for ageing BALB/c mice starting from week 15 that resulted 
in a significant difference when comparing results between weeks 5–
7 and 22–28 (p < 0.05). When BALB-neuT mammary glands 
progressed to invasive carcinoma, ADC values resulted significantly 
smaller in age-related BALB/c mice (p < 0.05). Figure 4b reports an 
increase in cellularity along BALB-neuT tumour progression. The 
average cell density was similar comparing BALB-neuT mammary 
glands at simple hyperplasia to atypical hyperplasia (535 ± 52 for 
simple hyperplasia and 548 ± 72 for atypical hyperplasia). When 
mammary glands progressed to CIS and invasive carcinoma, cellular 
density increased (775 ± 48 and 1009 ± 109 for CIS and invasive 
carcinoma), with statistical significant difference when comparing 
invasive carcinoma with simple hyperplasia and atypical hyperplasia 
(p < 0.001). Microvessel density (MVD) markedly increased 
with breast tumour progression from simple to atypical 
hyperplasia in BALB-neuT mice 
MVD significantly increased (p < 0.005) progressing from simple to 
atypical hyperplasia in BALB-neuT mice (MVD = 36 ± 6 and 149 ± 28 
for simple and atypical hyperplasia, respectively; Fig. 5a). This 
difference was maintained along the further stages of tumour 
progression (MVD = 151 ± 28 in CIS and 139 ± 15 in invasive 
carcinoma, p < 0.05, respectively). Similarly, percentage of total 
vessels per area showed an increased vascularization from simple to 
atypical hyperplasia, CIS and invasive carcinoma (Fig. 5b). 




The goal of our work was to evaluate whether vascular and cellular 
changes along mammary tumour progression stages in a transgenic 
mouse model of breast cancer could be assessed by applying 
different functional MRI techniques. We found that DCE-MRI was 
able to detect differences in vascularity when mammary glands 
progressed from the histological stage of simple hyperplasia to 
atypical hyperplasia. The observed differences were maintained 
between atypical hyperplasia, CIS and invasive breast cancer of 
BALB-neuT and normal mammary glands of control mice at the same 
week of age. These findings demonstrated the great potential of 
functional MRI methods for the detection of early changes 
associated to breast cancer and characterization of tumour 
progression stages in vivo, providing new insights into tumour 
angiogenesis and microenvironment changes. 
Many efforts are currently made to improve breast cancer screening. 
Although mammography is widely used in clinical settings for breast 
cancer detection, it suffers for poor sensitivity and low accuracy, in 
particular in presence of dense breast tissue.[29] Among the several 
imaging technique, MRI provides a great potential for the 
visualization of early breast cancer. Jansen et al.[30] demonstrated 
MRI capability to anatomically detect left inguinal mammary glands 
progression from in situ neoplasia to invasive carcinoma predicting 
the tumour invasiveness in the SV40 T-antigen transgenic breast 
cancer mouse model, whereas more recently Fan and colleagues[31] 
extended the study to all mammary glands by using a whole-body 
MRI operating at 9.4 Tesla. We deemed of interest to seek for 
functional information in addition to anatomical characterization by 
getting more insights into the angiogenesis process that goes along 
tumour growth and progression. Bachawal and colleagues[32] 
recently showed that targeted ultrasound contrast microbubbles for 
VEGFR2 allows detection and staging in a breast cancer transgenic 
mouse model. MRI-based approaches have been successfully 
exploited to monitor neovascularity or antivascular treatments.[33, 
34] In our study, we used Dynamic Contrast Enhanced (DCE)-MRI 
technique which reports about vascular volume and vessels leakiness 
of tumour vasculature thanks to the contrast enhancement 
generated by the injected blood pool MRI CAs. To the best of our 
knowledge, this is the first study able to detect functional vascular 
changes at early step of breast carcinogenesis in transgenic breast 




In our study we used the BALB-neuT transgenic mouse model, which 
mimics the slow step by step progression of human ductal breast 
adenocarcinoma from normal to simple hyperplasia, atypical 
hyperplasia, carcinoma in situ and invasive breast cancer (Fig. 1). 
Compared to other transgenic mouse models (e.g., SV40 T-antigen, 
that recapitulates the same progression in a shorter time-frame) 
mammary glands of the BALB-neuT mice progress along the different 
histological stages with a slow rate, showing the first palpable mass 
at 20 weeks of age.[22] Since this slow transformation closely 
reflects breast cancer development in patients, the angiogenic 
vasculature proceeds along with tumour progression in a more 
natural evolution path. Our results showed microvasculature 
changes in terms of permeability and vascularization when 
mammary glands progressed from simple hyperplasia to atypical 
hyperplasia. In particular, the volume transfer constant Ktrans and the 
plasmatic volume vp obtained by DCE-MRI considerably increased in 
BALB-neuT mice from the hyperplasia step, whereas their values 
remained stable in age-matched BALB/c control mice. In the BALB-
neuT mouse model, the angiogenic switch occurs at 8–10 weeks of 
age, when mammary glands show atypical hyperplasia.[35, 36] The 
formation of new blood vessels is a crucial step for tumour growth 
and proliferation, since it provides oxygen and nutrients and offers a 
route for tumour cells to disseminate through blood stream for 
invasion of distant organs. The angiogenic switch ensures this 
transition from pre-vascular hyperplasia to highly vascularised and 
outgrowing tumours. Our finding highlighted the ability of the MRI 
approach to detect in vivo such angiogenic switch, showing a marked 
increase in the DCE-MRI pharmacokinetic parameters in 
correspondence to the transition step from simple to atypical 
hyperplasia. A significant increase of MVD was observed when 
mammary glands progressed from simple hyperplasia to atypical 
hyperplasia, confirming the in vivo results. Our data are in 
accordance with a recent work of Conti and colleagues[37] that, by 
exploiting a new optical imaging probe targeting the angiogenesis 
marker αvβ3 integrin, showed early detection of mammary lesions at 
12 weeks of age in BALB-neuT mice. In our study, the combination of 
a blood pool CA with the DCE-MRI approach for functional 
microvasculature characterization of the mammary glands allowed 
the assessment of the angiogenic switch already at the 8–10 weeks 
of age. The microvasculature estimates obtained by DCE-MRI 
generally remained higher in the further stages of breast tumour 
progression, such as CIS and invasive breast cancer. A similar trend 
was observed from ex vivo quantification of mammary glands 
vessels, confirming DCE-MRI findings (Figs. 5a and 5b). Taken 
together, our results were in accordance with recent studies in 
human breast cancer reporting that the angiogenic initiation starts at 
the hyperplasia stage with a further increase of angiogenesis upon 
the transition from carcinoma in situ to invasive carcinoma.[38, 39] 
By contrast, the calculated semi-quantitative AUC estimates did not 
detect significant differences among the histological stages of 
tumour progression. Our results demonstrated that quantitative 
pharmacokinetic estimates could provide robust assessment of early 
vascular changes. Therefore, this approach represents a reliable tool 
to investigate functional vessel remodelling processes. 
Wild type BALB/c mice, used as controls in the present study, 
showed a decrease of both Ktrans and vp values at the age 
corresponding to CIS and invasive breast cancer in BALB-neuT mice. 
We surmise that the decrease in the functional parameters could be 
influenced by the loss of parenchyma as a consequence of the 
atrophy process of mammary glands in adult mice. The loss of 
parenchyma is generally followed by a loss of vascularization, likely 
resulting in a decrease of the MRI functional estimates.[40] A 
decrease of ADC values was observed in normal mammary glands 
along ageing of BALB/c mice (Fig. 3). Since the ageing of normal 
mammary glands is characterized by a loss of parenchyma and 
vascularization, we hypothesize that the reduced perfusion of the 
microcapillary network at later stages could contribute to the 
decrease of ADC in normal mammary glands. 
During BALB-neuT mammary tumour progression, a high percentage 
of normal tissue was still present in the mammary gland (Fig. 1). This 
is likely due to the slow progression rate of the neoplastic 
transformation process as well as to the fact that it does not affect 
synchronically all the acinar-lobular units. However, changes in 
vascularization accompanying breast cancer progression were 
successfully detected by our approach. Therefore, our results 
highlighted DCE-MRI ability to detect pathological breast tissue even 
if breast lesions represented only a small fraction of the whole 
mammary gland. This particular stromal morphological feature may 
explain the lack of correlation between DW-MRI with histologically 
determined cellularity along tumour progression stages of BALB-
neuT mammary glands. Moreover, we cannot exclude that ADC value 
might also depend on tumour stromal features. In addition to cell 
density, ADC values can be influenced by tissue perfusion, 
extracellular space and cell membrane integrity.[41] 
In this study we used a new Gd-based CA able to reversibly bind to 
serum albumin by forming a macromolecular adduct.[25] It is known 
that macromolecular tracers, in comparison to small size ones, allow 
for better assessment of the tumour vasculature permeability[42]; 
their accumulation in the tumour tissue is due to the 
hyperpermeability of tumour vasculature and the retention effect, 
resulting in a more effective tumour delineation.[43] The use of 
supramolecular paramagnetic adducts results in dramatic contrast 
efficiency at low magnetic fields (0.5–1.5 T).[44-46] Therefore, the 
high sensitivity of blood pool CA for the tumour vasculature 
characterization combined with the use of a 1 T magnetic field 
scanner may facilitate the translation of our approach to the clinical 
settings, in comparison to previous studies where high field scanners 
were employed. Previous studies from Jansen and colleagues[47] 
combined DCE-MRI with X-ray fluorescence microscopy to quantify 
the spatial distribution of CA in mammary glands of transgenic mice. 
Although gadolinium uptake in ducts allowed carcinoma in situ 
identification, no significant changes in pharmacokinetic parameters 
were reported mainly due to the small size of the employed CA. 
We acknowledge some limitations of our study. First, MRI 
acquisitions were limited to the forth right and left mammary glands 
of transgenic and control mice. BALB-neuT mice displayed a 
complete mammary tumour penetrance in all ten mammary glands, 
even if tumour progression is not simultaneous for all of them. We 
investigated only these mammary glands to avoid undesired 
artefacts flow related to movement during DCE-MRI acquisition. 
Second, DW-MRI images were acquired without fat signal 
suppression, which may lead to underestimated ADC values.[48] 
However, we suppose that this underestimation likely affected in a 
similar amount ADC values for both normal and neoplastic mammary 
glands. Third, DCE-MRI data could have been subjected to partial 
volume effect that occurs due to motion artefacts and to slice 
thickness; however, this is a much smaller effect in mice compared 
with human data. 
In summary, the current study highlighted the potential of functional 
MRI as a sensitive modality for tumour microenvironment 
characterization. In particular, our results outlined the ability of DCE-
MRI to detect tumour angiogenesis initiation in a transgenic breast 
cancer mouse model. Ktrans and vp values significantly increased when 
mammary glands evolved from hyperplasia to atypical hyperplasia; 
this transition was confirmed by an increase of MVD, which is a 
clinical surrogate marker for assessing tumour angiogenesis. In 
addition, our approach was able to detect the angiogenic switch in 
spite of the fact that only a small portion of the mammary gland 
tissue progressed to a neoplastic stage, thus providing a real non-
invasive approach for early breast cancer detection. Considering that 
the BALB-neuT model shares genetic and phenotypic similarities with 
human breast cancer, evaluation of vascularization/permeability in 
this model could have strong impact for understanding the 
pathophysiology of breast cancer during carcinogenesis. 
